This document lists the medicines eligible for supply through the Northern Ireland MHRA Authorised Route (NIMAR).
From 1 January 2022, the listed medicines may be dispatched from Great Britain to Northern Ireland on the basis of the medicines authorisation in Great Britain.
This list is maintained and published in accordance with regulation 167B (list of NIMAR products) of the Human Medicines Regulations 2012 (SI 2012/1916, as amended).
Published 16 December 2021 Last updated 4 April 2023 +show all updates
The following products have been added to the list: (Benlysta 200mg/1ml solution for injection pre-filled pens) Belimumab 200mg/1ml solution for injection pre-filled disposable devices, (Toujeo 300units/ml solution for injection 3ml pre-filled DoubleStar pens) Insulin glargine 300units/ml solution for injection 3ml pre-filled disposable devices, and (Orkambi 75 mg/94 mg granules in sachet) Lumacaftor 75 mg/Ivacaftor 94 mg granules sachet. The following product has been removed from the list: (Remsima 100mg powder for concentrate for solution for infusion vials) Infliximab 100mg powder for solution for infusion vials.
The following products have been added to the list: Buprenorphine 128mg/0.36ml prolonged-release solution for injection pre-filled syringes; Buprenorphine 160mg/0.45ml prolonged-release solution for injection pre-filled syringes; Buprenorphine 16mg/0.32ml prolonged-release solution for injection pre-filled syringes; Buprenorphine 24mg/0.48ml prolonged-release solution for injection pre-filled syringes; Buprenorphine 32mg/0.64ml prolonged-release solution for injection pre-filled syringes; Buprenorphine 64mg/0.18ml prolonged-release solution for injection pre-filled syringes; Buprenorphine 8mg/0.16ml prolonged-release solution for injection pre-filled syringes; Buprenorphine 96mg/0.27ml prolonged-release solution for injection pre-filled syringes
Added: (Remsima 120mg/1ml solution for injection pre-filled pens) Infliximab 120mg/1ml solution for injection pre-filled disposable devices.
Added: (Byetta 10micrograms/0.04ml solution for injection 2.4ml pre-filled pens) Exenatide 10micrograms/0.04ml solution for injection 2.4ml pre-filled disposable devices; (Byetta 5micrograms/0.02ml solution for injection 1.2ml pre-filled pens) Exenatide 5micrograms/0.02ml solution for injection 1.2ml pre-filled disposable devices; Hydroxycarbamide 100mg tablets.
Added: Avalglucosidase alfa 100mg powder for solution for infusion vials; Etoposide 100mg/5ml solution for infusion vials.Removed: (Truxima 500mg/50ml concentrate for solution for infusion vials) Rituximab 500mg/50ml solution for infusion vials.
Added: Canagliflozin 100mg tablets and Canagliflozin 300mg tablets. Removed (Toujeo 300units/ml solution for injection 3ml pre-filled DoubleStar pens) Insulin glargine 300units/ml solution for injection 3ml pre-filled disposable devices; Upadacitinib 45mg modified-release tablets; and (Plavix 75mg tablets) Clopidogrel 75mg tablets.
Updated to add (Plavix 75mg tablets) Clopidogrel 75mg tablets.
Removed from the list: Patisiran 2 mg/ml concentrate for solution for infusion. Added to the list: Methotrexate 1g/10ml solution for injection vials and Methotrexate 5g/50ml solution for infusion vials.
Updated to add 'Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) dispersion for injection' and to remove 'Cell-based quadrivalent influenza vaccine (surface antigen, inactivated) suspension for injection 0.5ml pre-filled syringes'.
The following medicine has been added to the list: (Toujeo 300units/ml solution for injection 3ml pre-filled DoubleStar pens) Insulin glargine 300units/ml solution for injection 3ml pre-filled disposable devices, and the following 6 medicines have been removed from the list: (HyQvia 10g/100ml solution for infusion and 5ml vials) Normal immunoglobulin human 10g/100ml solution for infusion vials and Recombinant human hyaluronidase solution for infusion 5ml vials, (HyQvia 2.5g/25ml solution for infusion and 1.25ml vials) Normal immunoglobulin human 2.5g/25ml solution for infusion vials and Recombinant human hyaluronidase solution for infusion 1.25ml vials, (HyQvia 30g/300ml solution for infusion and 15ml vials) Normal immunoglobulin human 30g/300ml solution for infusion vials and Recombinant human hyaluronidase solution for infusion 15ml vials, (HyQvia 5g/50ml solution for infusion and 2.5ml vials) Normal immunoglobulin human 5g/50ml solution for infusion vials and Recombinant human hyaluronidase solution for infusion 2.5ml vials, (Fotivda 1340microgram capsules) Tivozanib 1340microgram capsules, and (
